Ultime notizie per Borqs Technologies (OTC:BRQSF) Azioni

Borqs Technologies Inc is a provider of software development services and products, providing customizable, differentiated, and scalable Android-based smart connected devices and cloud service solutions. The company generates revenue in the form of software, and hardware revenue. A substantial portion of its revenue is generated in the form of hardware revenue which it earns for manufacturing customized products like trackers and smart watches, ruggedized handsets, tablets and smart phones, and mobile connectivity modules for its customers. Its geographical segments include the United States which is its key revenue-generating market, China, India, and the rest of the world.

BORQS TECH CORP by Borqs Technologies, Inc.

Borqs Technologies Inc

WIIM

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics shares are trading higher after the company announced that the FDa granted it Fast Track designation for ATH434 for the treatment of Multiple System Atrophy.

Morgan Stanley analyst Vincent Andrews maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Equal-Weight and lowers the price target from $94 to $80.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on DuPont de Nemours, Lowers Price Target to $80

Macro Economic Events

Market Summary

Economics

General

BRK/A

BRK/B

NFLX

Benzinga Market Summary: Abel To Succeed Buffett As Berkshire CEO, Oil Slips On OPEC+ Production Increase Plans, Film And Streaming Stocks On Watch Amid President Trump's Plans To Tariff Films Produced Outside The US

Morgan Stanley analyst Nathan Feather maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Overweight and raises the price target from $435 to $515.

DUOL

Morgan Stanley Maintains Overweight on Duolingo, Raises Price Target to $515

Guggenheim analyst Jason Cassorla reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) from Buy to Buy.

Reiteration

Guggenheim Reiterates Buy on Cigna Groupto Buy

Morgan Stanley analyst Tejas Savant maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Equal-Weight and lowers the price target from $8 to $7.

CYRX

Morgan Stanley Maintains Equal-Weight on CryoPort, Lowers Price Target to $7

Guggenheim analyst Joseph Osha reiterates MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Buy and maintains $195 price target.

Guggenheim Reiterates Buy on MasTec, Maintains $195 Price Target

Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/vrtx/earnings">closing bell on Monday, May 5.</a>
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.29 per share, down from $4.76 per share in the year-ago period. Vertex Pharmaceuticals projects to report quarterly revenue at $2.86 billion, compared to $2.69 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 28, Vertex Pharmaceuticals announced updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, including of explanted devices.
Vertex Pharmaceuticals shares gained 0.5% to close at $501.15 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/vrtx/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Cantor Fitzgerald analyst Carter Gould assumed an Overweight rating with a price target of $535 on April 22, 2025. This analyst has an accuracy rate of 60%.</li>
<li>B of A Securities analyst Ying Huang maintained a Buy rating and raised the price target from $555 to $567 on March 31, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Joon Lee maintained a Buy rating and increased the price target from $460 to $520 on Feb. 11, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $450 to $459 on Feb. 11, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight with a price target of $460 on Jan. 30, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="623" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05032748/image-32-1024x623.png" alt="" class="wp-image-900723" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05032748/image-32-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05032748/image-32-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05032748/image-32-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05032748/image-32.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

VRTX

Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

<a href="https://www.wolfpackresearch.com/_files/ugd/b084d8_d4e631542dd14b4389ea6273b3ee3543.pdf" title="https://www.wolfpackresearch.com/_files/ugd/b084d8_d4e631542dd14b4389ea6273b3ee3543.pdf">https://www.wolfpackresearch.com/_files/ugd/b084d8_d4e631542dd14b4389ea6273b3ee3543.pdf</a>

Short Sellers

UFPT

Watching UFP Technologies; Wolfpack Research Issues Report, Stating They Have A Short Position

XRP is starting the week under pressure, falling 2.21% to $2.14 on Monday and extending its seven-day decline to 7.5%. Despite holding nearly flat on the month, the altcoin has struggled to regain traction above $2.20 as <a href="https://www.benzinga.com/money/how-to-buy-ripple-xrp#:~:text=To%20purchase%20XRP%20on%20a,your%20assets%20as%20the%20custodian.">bearish sentiment takes hold across the market.</a>
Much of that caution stems from a notable increase in short interest. According to Coinglass data, XRP's long/short ratio has remained below 1 for nearly two weeks, most recently clocking in at 0.93.&nbsp;
Short Sellers Dominate Market Mood
That indicates more traders are betting on downside than upside—a signal of mounting skepticism. Adding to that, sentiment across social channels has stayed negative. XRP's weighted sentiment reading is currently at -0.40, highlighting a lack of bullish conviction and ongoing sell-side pressure.
The pessimism runs opposite to the optimism seen earlier this year, when hopes for a spot XRP ETF helped send the token above $2.30. While the U.S. Securities and Exchange Commission delayed a decision on the Franklin Templeton XRP ETF last week, prediction markets still see it as a likely approval.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
As of Monday, Polymarket bettors gave the fund a 76% chance of being approved by the end of 2025.
Still, some analysts see near-term headwinds. &#8220;XRP and Bitcoin bounced back from the tariff shocks in April, but have yet to make a significant movement upwards,&#8221; Nick Ruck, director at LVRG Research, said to CoinDesk. "Investors may be overly cautious about risk assets such as crypto due to the current US macroeconomic climate."
The broader crypto market opened the week on the defensive. Bitcoin remains trapped between $93,000 and $95,000 as traders await developments in U.S.–China trade negotiations. Thin trading volumes due to public holidays across Asia further dampened momentum.
XRP, meanwhile, is flirting with a critical psychological level at $2. If current market conditions persist, the token risks slipping below this threshold, with technical indicators pointing to potential support at $1.99 and $1.61.
Still, a reversal is not off the table. A sustained shift in demand could help XRP climb back above the $2.29 resistance level, potentially setting up a test of the $2.50 mark.
While short interest remains elevated and social sentiment is muted, XRP's next move will likely hinge on broader market catalysts, including risk appetite around <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45192936/wall-street-veteran-investor-lowers-recession-risk-as-us-china-trade-war-cools">U.S. macroeconomic policy and geopolitical negotiations</a>.
More Opportunities:
<ul>
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

XRP Slides Below $2.15 as Bearish Sentiment Builds

U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Monday.
Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/NSSC/earnings">first-quarter financial results</a>.
NAPCO Security Techs reported quarterly earnings of 28 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $43.96 million which beat the analyst consensus estimate of $43.14 million.
Napco Security Technologies shares jumped 9.6% to $26.06 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares jumped 25% to $61.66 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) gained 12.2% to $10.02 after the company reported a first-quarter sales beat.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) gained 10% to $11.44.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) gained 9.2% to $3.67.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) climbed 8.7% to $124.64.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) rose 7.7% to $22.84.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) shares gained 7% to $16.09.</li>
<li>Tsakos Energy Navigation Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) gained 6.2% to $18.13.</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) climbed 5.4% to $4.2050. The company posted upbeat quarterly earnings on Friday.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) gained 5.2% to $54.69. Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises from Hold to Buy and raised the price target from $54 to $67.</li>
<li>Tsakos Energy Navigation Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) shares rose 4.9% to $17.90.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

BCRX

NSSC

NUTX

PONY

ULCC

Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is suddenly looking like the hottest prescription in town &#8211; up 220% in the past year and turning heads with a bold new partnership that might just <a href="https://www.benzinga.com/general/health-care">reshape digital healthcare</a>.
The company <a href="https://investors.hims.com/news/news-details/2025/Hims--Hers-and-Novo-Nordisk-Team-Up-to-Expand-Affordable-Access-to-Care/default.aspx">announced</a> a long-term collaboration with pharmaceutical heavyweight Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), kicking off with a bundled offering of FDA-approved weight-loss drug Wegovy. For $599/month, customers get the medication, 24/7 clinical access and lifestyle coaching &#8211; all via the Hims &amp; Hers platform.
Related: <a href="https://www.benzinga.com/25/04/45074872/hims-hers-stock-surges-as-it-collaborates-with-novo-nordisk-to-sell-weight-loss-drug-wegovy-on-its-platform">Hims &amp; Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform</a>
<h2 class="wp-block-heading">Amazon&#8217;s Playbook At Work</h2>
It's a move straight out of Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) playbook: Build trust with accessible, affordable services, scale quickly, and monetize the ecosystem.
As Capitalist-Letters writer Oguz O. <a href="https://x.com/thexcapitalist/status/1917935673400611150">noted</a> on X, Amazon didn't just sell cheap books &#8211; it built Prime. Now, Hims is doing the same in healthcare, using tech to transform chronic care delivery into a consumer experience.
More importantly, this deal isn't one-and-done. It's the first step in a broader roadmap to expand Hims' reach far beyond obesity care. With Novo Nordisk in its corner and the infrastructure already in place, Hims is positioning itself to scale into other therapeutic areas—diabetes, hormonal treatments, mental health and beyond.
<h2 class="wp-block-heading">HIMS Stock Chart Bullish, Valuation Looks Attractive</h2>
Investors are taking note. Not only is HIMS stock trading above all key moving averages (eight, 20, 50 and 200-day), but the stock is flashing bullish across the technical board. With momentum like this, it's no surprise bulls are projecting 30% annual revenue growth, leading to $5.5 billion in revenue by 2030. 
Slap on a 20% margin and a 25x P/E multiple, and you're looking at a $27 billion company &#8211; up from today's $7 billion valuation, Oguz noted.
Hims seems poised to move beyond the health business into a healthcare delivery empire. The Amazon of medicine might be arriving sooner than expected—and it's not coming in two days—it's already here.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45147390/ge-healthcares-strong-q1-took-back-seat-to-tariffs-analyst-sees-2026-tariff-impact-less-than-2025">GE HealthCare&#8217;s Strong Q1 Took Back Seat To Tariffs, Analyst Sees 2026 Tariff Impact Less Than 2025</a></li>
</ul>
Photo: Shutterstock

Biotech

Long Ideas

Health Care

Technicals

AMZN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery

Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) has outperformed the market over the past 5 years by 16.35% on an annualized basis producing an average annual return of 30.37%. Currently, Cadence Design Systems has a market capitalization of $85.19 billion. 
Buying $100 In CDNS: If an investor had bought $100 of CDNS stock 5 years ago, it would be worth $381.65 today based on a price of $310.55 for CDNS at the time of writing.
<h3>Cadence Design Systems's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746454522_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDNS

Here's How Much $100 Invested In Cadence Design Systems 5 Years Ago Would Be Worth Today

Morgan Stanley analyst Brian Nowak maintains Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) with a Equal-Weight and lowers the price target from $40 to $36.

CRTO

Morgan Stanley Maintains Equal-Weight on Criteo, Lowers Price Target to $36

Scotiabank analyst Jonathan Goldman maintains TerraVest Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TVK#TSX">TVK</a>) with a Sector Outperform and raises the price target from C$141 to C$171.

TSX:TVK

Scotiabank Maintains Sector Outperform on TerraVest Industries, Raises Price Target to C$171

UMAC

Unusual Machines shares are trading lower after the company announced it priced a $40 million offering of 8 million shares at $5.00 per share.

Morgan Stanley analyst Erin Wright maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $379 to $390.

Morgan Stanley Maintains Overweight on Cigna Group, Raises Price Target to $390

Scotiabank analyst Konark Gupta maintains Secure Waste Infr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SES#TSX">SES</a>) with a Sector Outperform and lowers the price target from C$19.5 to C$19.

TSX:SES

Scotiabank Maintains Sector Outperform on Secure Waste Infr, Lowers Price Target to C$19

Scotiabank analyst Orest Wowkodaw maintains Lundin Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LUN#TSX">LUN</a>) with a Sector Outperform and raises the price target from C$13 to C$14.

TSX:LUN

Scotiabank Maintains Sector Outperform on Lundin Mining, Raises Price Target to C$14

Worthington Enterprises shares are trading higher after Canaccord Genuity upgraded the stock from Hold to Buy and raised its price target from $54 to $67.

Comments

Borqs Technologies

Notizie

Ultime notizie per Borqs Technologies (OTC:BRQSF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO